Mrsa | MRSA Test Company Closes $2.3M Investment


Tennessee transplant NanoDetection Technology has cashed in on the promise of an investment that drew it to Ohio earlier this year and has closed on a $2.3 million series A round of funding.

The Cincinnati-area company is developing a low-cost, point-of-care diagnostic test for MRSA (Methicillin-resistant Staphylococcus aureus) to be sold to hospitals and physicians’ offices, according to a statement. MRSA is a bacterial infection that is highly resistant to some antibiotics and is often referred to as a ” superbug .”


The funding, which was led by a $400,000 contribution from CincyTech , will go toward clinical trials aimed at obtaining regulatory clearance for the MRSA test, according to a statement from NanoDetection Technology.

The company had originally targeted $2 million for its series A round, but strong investor interest drove the amount up to $2.3 million. A


Click here to view rest of article from original site

Nostalgie Nostalgie



Facebook Twitter Email